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Abstract
Background: Clinician-scientists play an important role in translating between research and clinical practice. Significant
concerns about a decline in their numbers have been raised. Potential barriers for career entry and progress are explored in
this study.
Methods: Case-study research methods were used to identify barriers perceived by clinician-scientists and their research
teams in two Canadian laboratories. These perceptions were then compared against statistical analysis of data from
Canadian Institutes of Health Research (CIHR) databases on grant and award performance of clinician-scientists and non-
clinical PhDs for fiscal years 2000 to 2008.
Results: Three main barriers were identified through qualitative analysis: research training, research salaries, and research
grants. We then looked for evidence of these barriers in the Canada-wide statistical dataset for our study period. Clinician-
scientists had a small but statistically significant higher mean number of degrees (3.3) than non-clinical scientists (3.2),
potentially confirming the perception of longer training times. But evidence of the other two barriers was equivocal. For
example, while overall growth in salary awards was minimal, awards to clinician-scientists increased by 45% compared to
6.3% for non-clinical PhDs. Similarly, in terms of research funding, awards to clinician-scientists increased by more than 25%
compared with 5% for non-clinical PhDs. However, clinician-scientist-led grants funded under CIHR’s Clinical thematic area
decreased significantly from 61% to 51% (p-value,0.001) suggesting that clinician-scientists may be shifting their attention
to other research domains.
Conclusion: While clinician-scientists continue to perceive barriers to career entry and progress, quantitative results suggest
improvements over the last decade. Clinician-scientists are awarded an increasing proportion of CIHR research grants and
salary awards. Given the translational importance of this group, however, it may be prudent to adopt specific policy and
funding incentives to ensure the ongoing viability of the career path.
Citation: Lander B, Hanley GE, Atkinson-Grosjean J (2010) Clinician-Scientists in Canada: Barriers to Career Entry and Progress. PLoS ONE 5(10): e13168.
doi:10.1371/journal.pone.0013168
Editor: Nandi Siegfried, Medical Research Council South Africa, South Africa
Received May 4, 2010; Accepted August 23, 2010; Published October 4, 2010
Copyright:  2010 Lander et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: The research was funded by Genome Canada (www.genomecanada.ca) under Competition 3, as part of the Pathogenomics of Innate Immunity project
(http://www.genomebc.com/portfolio/projects/health-projects/current/the-pathogenomics-of-innate-immunity-pi2/). The funders had no role in study design,
data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: janetat@interchange.ubc.ca
Introduction
A gap exists between health research and clinical practice.
While scientists constantly produce new knowledge relevant to
clinical care, much of their work is never incorporated into
practice [1,2]. Similarly, clinical problems are rarely translated
into research projects [3]. Clinician-scientists play an important
role in filling this gap because they split their time and interests
between clinical practice and research, enabling them to translate
their research results into the clinic and to develop research
questions based on clinical issues they encounter in practice [4–7].
Thus, much attention has been paid to the role of the clinician-
scientist in research translation. Significant concern has been
expressed over the last three decades about barriers faced by
clinician-scientists and indeed their very survival. Both within
Canada and the United States reports and articles on clinician-
scientists point to a decreasing workforce, a lack of research grants,
and clinician-scientists moving away from patient-based research
towards basic science or health services research [5,7–12].
In Canada, reports of a significant drop in the percentage of
grantees with an MD or MD/PhD from Canada’s major medical
funding agency at the time, the Medical Research Council (MRC),
began receiving attention over a decade ago [5]. However, the
reform of Canada’s medical research funding in 2000, which
transformed the MRC into the Canadian Institutes of Health
Research (CIHR), was accompanied by substantial reinvestments
in Canadian health research [13]. Despite these reforms, the
viability of patient-based research by clinician-scientists continues
to be questioned [14]. It has been suggested that there are fewer
clinician-scientists conducting research in Canada today than
before the reforms. There have also been reports that clinician-
scientists are turning away from the CIHR’s Clinical thematic
research area towards the other three foundational domains:
Biomedical; Health Systems and Services; and Population and
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scientists less likely to capitalize on their ability to conduct research
relevant to the clinic and translate this research into clinical
practice [10,14].
Canadian physician and hospital care is covered by a universal
public health insurance program which pays doctors primarily
through fee-for-service mechanisms. Universities are also publicly
funded with operating costs predominately provided on a
provincial basis and research predominately funded through
federal grant agencies such as CIHR. Canada has eighteen
medical schools that are affiliated with hospitals. Many Canadian
clinician-scientists work within these affiliated hospitals and may
fulfill the three social missions of teaching, research, and care.
Other clinician-scientists follow different career paths. Some
clinician-scientists have faculty positions, others rely on grants
and clinical practice for their salaries and may not be involved in
teaching; some clinician-scientists devote the majority of their time
to research, others are predominately focused on clinical care [8].
Given the importance of clinician-scientists to the development
of clinically relevant research questions and the translation of these
findings into practice, we felt it was important to understand
whether, following the advent of CIHR, Canadian clinician-
scientists continue to face barriers to career entry and progress.
Due to a lack of high-quality data on the qualifications and
activities of CIHR investigators, past studies tended to extrapolate
clinician-scientist research trends from funding allocations among
the four thematic areas. However, using a dataset that includes
specific information on the training background of all CIHR
grantees between 2000 and 2008, we were able to identify all
Canadian clinician-scientists receiving CIHR support, regardless
of thematic area. Furthermore, past articles—written as commen-
tary and perspective pieces on the status of clinician-scientists—
tended to use either qualitative data from clinician-scientists [9] or
quantitative data on training and grants [5,7]. We believe it is
important to combine these two styles, using ‘‘mixed methods’’ to
generate a more nuanced understanding of the real and perceived
barriers faced by clinician-scientists in Canada. We adopted
qualitative methods to understand the barriers perceived by
particular clinician-scientists and their research teams and
quantitative methods to explore whether these perceived barriers
were supported in CIHR data.
Methods
Ethics approval for the qualitative case study was granted by the
Behavioural Research Ethics Board at the University of British
Columbia. All participants signed a consent form. Ethics approval
for the quantitative analysis was not required because it was
covered by the publicly available data clause (Item 1.3.1) of the
University of British Columbia’s Policy #89: Research and other
studies involving human subjects.
Qualitative Methods
The research reported on here derives from a nested case study
situated within a larger case study exploring the translational
activities of a network (6 nodes; 120 members) of clinician-
scientists, bioinformaticians, and basic scientists studying the
pathogenomics of innate immunity. (The PG-II Network.) Case
studies are concentrated enquiries investigating a particular
bounded entity or phenomenon. Studies of particular cases help
advance understanding of more general phenomena but are not,
by their nature, statistically generalizable. The nested case
described in this article focused on the two laboratories (LabA
and LabB) in the node that provided PG-II with a clinical
interface. LabA and LabB are located in a research institute on the
campus of an urban referral hospital. The clinician-scientists
heading the laboratories spend approximately 80% of their time
on research and the remaining 20% as immunological specialists
in the adjacent hospital. The purpose of the case was to identify
the translational practices mediating the clinical and research goals
of these particular clinician-scientists and their laboratories.
Qualitative data collection spanned February 2007 through
January 2008. First, face-to-face surveys were administered to all
16 scientists and technicians employed in the two laboratories at
the time of our visit. Subsequently, following analysis of the survey
data, in-depth semi-structured interviews were conducted with the
10 remaining members of the original sample–six graduate and
co-op students had, by this time, been rotated-out and replaced.
Survey and interview questions explored issues such as the
translational activities pursued within the lab; the role of funding
agencies in supporting the work; training experiences and roles
within the lab; and collaborations with other research groups. As
well, between May and August 2007, a period of participant
observation allowed us to monitor the formal and informal
mechanisms influencing the work of the laboratories, and
increased both the diversity of our data and our confidence in it.
In the follow-up phase (January 2009), we reinterviewed four
specific members of the team, selected on the basis of their
expertise and engagement in the translational areas we had chosen
for closer study: chronic granulomatous disease; IRAK-4 deficien-
cy; and the longstanding bacteria-identification service provided
by LabA to clinicians treating cystic fibrosis patients. Field notes,
open-ended survey responses, and interview transcripts were
coded with Atlas.ti qualitative data analysis software; we used
SPSS for statistical analysis of survey data.
Our qualitative coding matrix captured information on funding,
knowledge production, research culture, research values, training,
and the translational interface. To ensure reliability in applying
the matrix, one interview was separately coded by three members
of the team. Variations in coding application were discussed and
consistent definitions agreed upon. All transcripts were then coded
by one team member.
Quantitative Methods
To compensate for the case study’s lack of generalizability, we
accessed data from CIHR’s Funded Research database to look for
evidence of the barriers that clinician-scientists identified in the
qualitative findings. This database is publicly available online and
provides information on all funding granted by CIHR since its
inception in 2000. The CIHR database contains fields indicating
type of award (operating grant, training award, salary award, etc),
principal investigators (PI), co-applicants (Coap), primary thematic
areas, effective date of award, and monetary amounts funded for
each type of award in each fiscal year. (For example, if a five year
award with a total value of $500,000 was paid at a rate of $100,000 a
year, our data would indicate the $100,000 separately for each fiscal
year.) Through a special request to CIHR, we were also able to
obtain information on the degrees obtained by each of the re-
searchers in the dataset. These data indicate whether the researcher
has a Bachelor’s degree, a Master’s degree, an MD, a doctoral
degree in another health profession, a PhD, a fellowship, and
whether they have completed a Postdoctorate or are a Registered
Nurse. These fields are not mutually exclusive—researchers indicate
all the degrees/training that they have completed.
Using the data provided by CIHR, we built a dataset including
each unique investigator PIN, by degrees held, training and salary
awards funded, and the funding Institute for each thematic
domain of CIHR’s mandate: (1) Biomedical; (2) Clinical; (3)
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Health. Categorization of research into the four themes is made by
principal investigators when applying for grants. (See the CIHR
glossary [http://www.cihr.ca/e/34190.html#r7] for details on
how CIHR defines its four themes.) We calculated the total
amount of funding for grants in each of the four themes, as well as
the total amount of funding for training and salary awards across
the nine fiscal years of data we had accessed (00/01–08/09). In the
figures, we present both numbers of awards and dollars awarded as
all grants are not equal. Canadian dollars are used throughout.
We defined clinician-scientists broadly to include those
(including MDs and RNs) without a PhD and those with a PhD
(such as MD-PhDs or RN-PhDs). We then compared this group to
non-clinical scientists with PhDs in order to examine the perceived
barriers we had identified. This broad definition allowed us to
investigate the hypothesis that those trained as clinician-scientists
may be moving away from patient-based research in the Clinical
theme in favour of other CIHR thematic areas. Our definition is
also consistent with that used in similar previous studies [5,7],
allowing for greater comparability.
Data were summarized using descriptive statistics. We per-
formed statistical analyses to examine whether population means
were significantly different using Chi-squared tests for categorical
data and T-tests for normally distributed continuous variables.
Statistical significance was determined at P-value less than 0.05.
All analyses were performed using Stata version 10.0 (StataCorp,
College Station, TX).
Results
Perceived barriers identified in our qualitative research
A keytheme that emerged during dataanalysis wasthat clinician-
scientists, and their laboratory colleagues, perceive barriers unique
to their work. While we use representative quotes from the two
principal clinician-scientists to outline these barriers, our interviews
with laboratory colleagues and technicians supported their
observations and added depth to our understanding. These lab
workers saw firsthand, and were often affected by, the barriers
encountered by their principals. The clinician-scientists we
interviewed perceived high entry and maintenance barriers to their
chosen career path that would discourage new entrants.
If you look at historical trends, clinician-scientists are a dying
breed…the hard thing is to convince somebody to take this
on as a career. It’s hard enough to get funded as a basic
scientist who doesn’t have any clinical responsibilities. But to
continue to run a large research lab and have clinical
responsibilities is a daunting double life. A lot of people just
aren’t prepared to take that on.
Beyond the general challenges referenced in the above quote,
three major perceived barriers were identified from our field data,
related to (1) research training, (2) research salaries, and (3)
research funding.
Research training. It is often the case that clinician-scientists
complete medical training before starting research training. As a
result, just at the point when they can expect to realize significant
clinical earnings, and when many already carry sizeable student
loans, potential clinician-scientists must again defer financial
rewards. Our sources suggest that this combination of earnings
deferral and prolonged training acts as a significant disincentive
for prospective new recruits: ‘‘the major discouragement is poverty
and a very long training program.’’
Research salaries. Clinical faculty often earn significantly
more than research faculty. This is a problem for clinician-scientists
since universities tend to be reluctant to pay the clinical rate for
research work. As one clinician-scientist noted: ‘‘the university
doesn’t want to pay a research scientist much, much more [just]
because they have a medical degree.’’ Thus, for a research team,
finding moneyto pay clinician-scientists isoften the mostchallenging
part of hiring them. One solution, according to our sources, is to put
together the equivalent of a clinician’s salary on an ad hoc basis from
multiple research and clinical ‘‘pockets,’’ with CIHR as the deepest
pocket in the researchmix. These salary sources are often temporary
and arbitrary,however,withnoguaranteesofcontinuity.Informants
argue that formal payment plans need to be established for clinician-
scientists if the career path is to be a viable option.
Research funding. The playing-field for research funding is
viewed as far from level. Clinician-scientists, who spend part of
their time in patient-based practice, find themselves competing
with full-time research scientists. Funding applications are judged
on the research experience of the applicant; clinical experience is
not an important factor in these decisions. As one of our
informants noted:
You have to submit grants that will be fundable at the
national and international level, and papers that will be
published in internationally recognized journals. And the
journals or granting agencies don’t care much [about the
clinical part].
Thus, clinician-scientists felt they were less likely to accumulate
grants (and the publications essential to funding success) than
researchers with no clinical responsibilities whose focus was tied
intimately to the terms and conditions of the granting agencies. In
the words of one informant, ‘‘I’m competing with basic scientists;
I’m looking for the same CIHR dollars as somebody who has no
clinical responsibilities.’’ An administrator who helps scientists
improve their funding applications commented:
[For] a clinician-scientist who sees a problem in a patient
and then brings that into the lab…you have to be more
creative as to where you’re [looking for] funding because it
fits outside of the box.
He notes that review criteria tend to focus on factors like number
and quality of publications, numbers of trainees graduated. ‘‘[But]
number of clinical guidelines changed? [That doesn’t count.]’’
Are these perceived barriers borne out in the CIHR data?
Research Training. The clinician-scientists in our dataset
(n=4,522) did have a small but statistically significant higher
mean number of degrees than their non-clinical PhD counterparts
(n=8,346) (3.3 versus 3.2 p-value ,0.005). Combined MD/PhD
training programs represent an attempt to overcome the
disincentives of extended training by integrating the clinical and
research components. To address the problem of reduced earning
potential, CIHR has instituted specific clinician-scientist training
awards designed to support qualified clinicians interested in
pursuing a research career. The ‘Clinician Scientist Phase 1’
award provides a training stipend for up to 6 years, while the
‘Clinician Scientist Phase 2’ award is restricted to holders of Phase
1 awards, providing up to 6 years of salary support once training is
completed.
Our data indicate that CIHR funded a total of 127 MD/PhD
studentships between 00/01 and 08/09. The total amount spent
Clinician-Scientists in Canada
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awarded between 00/01 and 04/05, meaning that a smaller
number of awards have been made in the past four fiscal years.
With respect to the ‘Clinician Scientist Phase 1 award’, 87 award
winners received support over the study period at a mean annual
value of $43 thousand; there was no shift apparent in the number
of annual awards. During the same time frame, a total of 60
‘‘Clinical Scientist Phase 2’’ awards were granted worth a total of
$12.8 million with a mean annual value of $20.5 thousand.
Research salaries. CIHR funding for salary awards
remained relatively stable, increasing from approximately $29
million in 00/01 to $31 million in 08/09. Clinician-scientists
received approximately 34% of the salary awards (32% of total
dollars), while non-clinical PhDs received approximately 63% of
the awards (64% of total dollars.) While overall funding for salary
awards held fairly stable, clinician-scientists had the largest growth
rates in the category, increasing by a mean of 45.5% compared to
a mean of 6.3% for non-clinical PhDs. Salary award funding for
other researchers decreased over the study period. The mean
annual value of a CIHR-funded salary award was $53.6 thousand
and there was no significant difference in mean or median value
between clinician-scientists and non-clinical PhDs (p-value 0.11
and 0.32, respectively).
Research funding. Figure 1 illustrates the overall percentage
of total grant funding that went to clinician-scientists, non-clinical
PhDs and other researchers by fiscal year. The figure indicates
that funding to clinician-scientists grew slightly over the study
period, from approximately 28% of total funding in fiscal year 00/
01 to approximately 35% by 08/09. Over the same period, the
growth rate in grant funding for non-clinical PhDs was 5%
compared to 25% for clinician-scientists. The results are similar
when number of grants awarded are used, rather than monetary
values of the grants.
To examine the hypothesis that clinician-scientists are moving
away from CIHR’s Clinical thematic domain in favour of other
theme areas we examined the percentage of Clinical grants led by
at least one clinician-scientist across the entire study period.
Figure 2a indicates that the percentage decreased significantly
from 61% in 2000 to 51% in 2008 (p-value ,0.001). The number
of non-clinical PhDs leading Clinical research grants increased
from 32% to 46% in the same period (p-value ,0.001). The
percentage of Biomedical research grants led by clinician-scientists
remained relatively stable while Population and Public Health
grants grew slightly. However, grants under the Health Systems
and Services thematic area increased significantly, from 36% in
2000 to 46% in 2008 (p-value ,0.001) as indicated in Figure 2b.
Figure 3 shows the percentage of clinician-scientists’ funding
that comes from each of the CIHR thematic research areas. While
they may be moving towards other areas, clinician-scientists still
receive the majority of their funding from the Biomedical and
Clinical research themes; an average of 74% of their total funding
came from this combination.
Discussion
Our research suggests that a tension may exist between barriers
perceived by clinician-scientists and actual CIHR support for this
career category. The quantitative data for the period (00/01
through 08/09) suggest considerable stability and some growth in
research funding and training support for clinician-scientists.
Differences between the qualitative and quantitative findings may
be caused by a disconnect between the ‘lived experience’ of
individual clinician-scientists and what we detected at a broader
population level. For example, while our results show increasing
salary support for clinician-scientists, no significant differences
exist between median salary award amounts for clinician-scientists
and non-clinician PhDs. This levelling does little to remedy the
higher salaries paid to clinicians over scientists, a differential
known to act as a disincentive for clinicians thinking about a
research career [7,8,15].
The inconsistency between our qualitative and quantitative
findings might also be explained by a lack of awareness about
CIHR programs instituted to address the barriers, such as the
MD/PhD studentships and the Clinician Scientist Phase 1 and 2
awards. Declines in clinician-scientist rates did occur in Canada in
the 1980s and 1990s [5] and current perceptions may lag real
increases in support. Also, we lack data on the success rate of
applications to CIHR. A significantly lower success rate for
clinician-scientists compared to non-clinical peers might explain
why a barrier is perceived that is absent in the statistical data. Also,
our quantitative analysis examined only one source of funding
(CIHR) for clinician-scientists, excluding provincial funders (e.g.
Michael Smith Foundation for Health Research, Alberta Heritage
Foundation for Medical Research), disease organizations (e.g.
Heart and Stroke Foundation, Canadian Cystic Fibrosis Founda-
tion), as well as industry. While our analysis does not paint a full
picture of all funding sources in the country, CIHR is recognized
to be the largest single funder of health research grants in Canada
Figure 1. Funding to clinician-scientists, non-clinical PhDs, and other researchers between 2000/01 and 2008/09.
doi:10.1371/journal.pone.0013168.g001
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quantitative findings might be explained by the particularity of
case-study research methods. Our nested case was bounded by the
larger case of the PG-II network. In other words, our study was
confined to those clinician-scientist led laboratories within PG-II.
As a result, it involved colleagues working within the same
discipline, at the same organisation, and within the same research
network. While this tight focus provided a satisfying level of detail
and richness, we recognize that the barriers we identified may be
specific to the discipline or organisation. A study employing
comparative case methods might well produce different results.
Our results are consistent with Roy who noted a drop in clinician-
scientist grantees from over 40% to close to 33% between 1986
and 1995 [5]. Beginning in 00/01, we found that clinician-
scientists were collecting only 28% of CIHR grant money;
however, this percentage increased to 35% by 08/09. These
results suggest that the situation of clinician-scientists might have
worsened before beginning to recover. While our quantitative
analysis looked at trends over a nine year period, our qualitative
data explored barriers perceived by clinician-scientists today.
Their perception is that while barriers may have been lowered
since CIHR was founded, they still exist; this perception mirrors
some of the trends we found in the quantitative data.
Rosenberg argues that the bridging role played by clinician-
scientists in the United States sets the United States apart from
Japan and Europe [9]. This would also set Canada apart from
Japan and Europe. Consistent with previous findings for Canada
[5], in the United States clinician-scientist trainee and grant
applications to the National Institutes of Health (NIH) declined
between 1971 and 1978 [7], a trend which continued into the
1990s [9]. Again as in previous Canadian findings [10,14], the
proportion of clinician-scientists involved in clinical research in the
United States fell from 40% of NIH applications in 1972 to 25%
in 1997 [17]. Similar to recent CIHR initiatives in Canada,
between 1998 and 2002, a series of programs initiated by the NIH
and non-for-profit institutions focused on encouraging clinician-
scientist training [18]. While the number of clinician-scientists
conducting research remained flat into the early 2000s, there are
signs that more are entering the career pipeline [19]. Thus, the
cautious optimism shown in our results appears consistent with
recent trends within the United States. In England, clinician-
scientists appear to have received less attention [20] and we were
Figure 2. a: Percentage of clinical research grants led by clinician-scientists and non-clinical PhDs between 2000 and 2008.
b: Percentage of health systems and service research grants led by clinician-scientists and non-clinical PhDs between 2000 and 2008.
doi:10.1371/journal.pone.0013168.g002
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more focused on encouraging bridges between basic research and
clinical practice more generally as opposed to supporting clinician-
scientists specifically. Policy initiatives encouraging such bridges
date to the 1971 Rothschild Report [21] and more recently
through the creation of biomedical research centres that bring
England’s public health system and universities together [22].
The quantitative results of this study seem to paint a more
optimistic picture about the role of clinician-scientists in Canada’s
research enterprise than previous studies. Nevertheless, we found that
clinician-scientists and their trainees still perceive important barriers
to working in this area—barriers they believe act as fundamental
disincentivestowardspursuingcareersasclinician-scientists.Ourdata
show that while some progress has been made on some barriers, less
progress has been made on others. Many government programs and
policies have been implemented to addressthe impediments but these
have been piecemeal initiatives rather than an overarching strategy.
Individuals wishing a career as a clinician-scientist can pursue an
integrated MD/PhD program, short term research training, or
longer full term training. Subsequent salaries are often created
organization by organization on an ad hoc basis through a
combination of clinical fee schedules and research dollars [8].
In order to ease some of the barriers perceived by clinician-
scientists, our qualitative findings suggest that funding agencies
need to develop a method for evaluating research proposals that
does not penalise clinical work [8,17]. Connections to the clinic
provide a niche advantage for clinician-scientists and this area
should be emphasized in research policy and planning. Continuing
to broaden research training and salary award programs and
creating formal salary policies on an organizational level would
likely support continued growth in numbers of clinician-scientists.
This study represents an attempt to create a more nuanced
understanding of barriers perceived by clinician-scientists since the
advent of CIHR. As such, it represents a first of many potential
steps to further understand the issue. A qualitative study of
clinician-scientists involved in different disciplines and thematic
areas would help to show whether perceived barriers are similar or
different across the board. A longitudinal study would help to track
how perceptions change over time. Analyses of institutional
(university and hospital) policies on clinician-scientists would help
identify structural barriers. A quantitative study that develops a
dataset capable of including funding from disease organisations
and industry as well as CIHR, would paint a more comprehensive
picture of where clinician-scientists obtain their support.
Clinician-scientists play a vital role in translating between
clinical practice and discovery research. We believe their role
needs to be better understood and appreciated in a policy and
funding climate that promotes translational practices [23].
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